Literature DB >> 33022760

Prognostic Value of Tumor Proportion Score in Salivary Gland Carcinoma.

Fumihiko Sato1,2, Takeharu Ono1, Akihiko Kawahara3, Katsuhisa Matsuo2, Reiichiro Kondo2, Kiminobu Sato1, Jun Akiba3, Toshihiko Kawaguchi1, Tatsuyuki Kakuma4, Shun-Ichi Chitose1, Hirohito Umeno1, Hirohisa Yano2.   

Abstract

OBJECTIVE: Limited information is available regarding the role of programmed death ligand 1 (PD-L1) expression and CD8+ tumor-infiltrating lymphocyte (TIL) density in the tumor immune microenvironment (TIM) of patients with salivary gland carcinoma (SGC). This study aimed to assess the association between the prognosis of SGC patients and the probability of PD-L1 expression in tumor and/or immune cells using the tumor proportion score (TPS), mononuclear immune cell density score (MIDS), combined positive score (CPS), and CD8+ TIL density in the TIM. STUDY
DESIGN: Retrospective cohort study.
METHODS: We retrospectively reviewed 73 SGC patients treated with definitive surgery between 2000 and 2015. Immunohistochemical analysis was used to assess TPS, MIDS, CPS, and CD8+ TIL density, followed by prognostic evaluation of these immune-related parameters.
RESULTS: Histological grade was associated with TPS, MIDS, and CPS based on PD-L1 expression, and these scores exhibited a significant association with CD8+ TIL density. Patients with positive TPS had an unfavorable disease-free survival and overall survival. Multivariate analyses indicated that the TPS was a significant and independent prognostic factor.
CONCLUSION: Our results suggest that TPS might be a useful prognostic biomarker in SGC patients receiving definitive surgery. Laryngoscope, 131:E1481-E1488, 2021. @ 2020 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  CD8; PD-L1; Salivary gland carcinoma; head and neck cancer

Year:  2020        PMID: 33022760     DOI: 10.1002/lary.29120

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  4 in total

1.  Simultaneous Expression of PD-1 and PD-L1 in Peripheral and Central Immune Cells and Tumor Cells in the Benign and Malignant Salivary Gland Tumors Microenvironment.

Authors:  Mohammad Reza Haghshenas; Nasrollah Erfani; Sajjad Gerdabi; Fatemeh Asadian; Razie Kiani; Bijan Khademi
Journal:  Head Neck Pathol       Date:  2022-09-28

2.  Incidence and Prognostic Significance of PD-L1 Expression in High-Grade Salivary Gland Carcinoma.

Authors:  Qigen Fang; Yao Wu; Wei Du; Xu Zhang; Defeng Chen
Journal:  Front Oncol       Date:  2021-08-26       Impact factor: 6.244

3.  Prognostic role of PD-L1 expression in patients with salivary gland carcinoma: A systematic review and meta-analysis.

Authors:  Limeng Wu; Canhua Jiang; Zhihui Zhu; Yao Sun; Tao Zhang
Journal:  PLoS One       Date:  2022-07-26       Impact factor: 3.752

Review 4.  Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer.

Authors:  Siqing Jiang; Xin Li; Lihua Huang; Zhensheng Xu; Jinguan Lin
Journal:  Front Immunol       Date:  2022-09-02       Impact factor: 8.786

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.